Journal
JOURNAL OF MEDICINAL CHEMISTRY
Volume 65, Issue 19, Pages 13328-13342Publisher
AMER CHEMICAL SOC
DOI: 10.1021/acs.jmedchem.2c01131
Keywords
-
Categories
Funding
- German Center for Infection Research (DZIF) [TTU 09.719, TTU01.930]
- European Union [10100362]
- Government of Schleswig Holstein through its Structure and Excellence Fund
- Possehl Foundation (Lubeck)
- University of Lubeck
Ask authors/readers for more resources
This article discusses the potential application of inhibitors targeting the main protease (Mpro) of SARS-CoV-2 in COVID-19 treatment. The study found that 13b-K is an effective inhibitor and shows promise for further development as an antiviral treatment for COVID-19.
SARS-CoV-2 is the causative agent behind the COVID-19 pandemic. The main protease (Mpro, 3CLpro) of SARSCoV-2 is a key enzyme that processes polyproteins translated from the viral RNA. Mpro is therefore an attractive target for the design of inhibitors that block viral replication. We report the diastereomeric resolution of the previously designed SARS-CoV2 Mpro alpha-ketoamide inhibitor 13b. The pure (S,S,S)-diastereomer, 13b-K, displays an IC50 of 120 nM against the Mpro and EC50 values of 0.8-3.4 mu M for antiviral activity in different cell types. Crystal structures have been elucidated for the Mpro complexes with each of the major diastereomers, the active (S,S,S)-13b (13b K), and the nearly inactive (R,S,S)-13b (13b-H); results for the latter reveal a novel binding mode. Pharmacokinetic studies show good levels of 13b-K after inhalative as well as after peroral administration. The active inhibitor (13b-K) is a promising candidate for further development as an antiviral treatment for COVID-19.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available